Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134611

Published: 2020

Journal Articles

B7-H6 Is Associated with Poor Prognosis and a Potential Therapeutic Target of T-Lymphoblastic Lymphoma

Lei Yuan, Lu Sun, Yu Zhao, Hongmei Jing, MD PhD, Xiaoyan Ke, MD PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-139146

Published: 2020

Journal Articles

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Lung-Ji Chang, PhD, Lujia Dong, MD, Jun Zhu, MD, Zhitao Ying, MD, Hao-Hsian Kuo, MSc, Yuchen Liu, MSc, Yu-Qin Song, MD, Xiao-Pei Wang, MD, Yong-Qian Jia, MD, Ting Niu, MD PhD, Ting Liu, MDPhD, Ling Pan, MD, Zhuo-Gang Liu, MD, Tong Li, MD, Ying-Chun Li, MD, Kun Yao, MD, Xiaoyan Ke, MD PhD, Hongmei Jing, MD, Fang Bao, MD

Blood (2015) 126 (23): 264.

https://doi.org/10.1182/blood.V126.23.264.264

Published: 2015

Journal Articles

The Expression and Effect of B7-H3 in Mantle Cell Lymphoma

Jing Wang, Wei Zhang, Yanfang Wang, Fei Dong, Mingxia Zhu, Wenli Wan, Haisheng Li, Feifei Wu, Xinxing Yan, Xiao-Feng Yang, MD PhD FAHA, Xiaoyan Ke, MD PhD

Blood (2015) 126 (23): 4811.

https://doi.org/10.1182/blood.V126.23.4811.4811

Published: 2015

Journal Articles

B7-H3 Silencing By RNAi Inhibits Tumor Progression and Enhances Chemosensitivity in U937 Cells

Wei Zhang, Jing Wang, Yanfang Wang, Fei Dong, Mingxia Zhu, Wenli Wan, Haishen Li, Feifei Wu, Xinxing Yan, Xiao-Feng Yang, MD PhD FAHA, Xiaoyan Ke, MD PhD

Blood (2015) 126 (23): 4813.

https://doi.org/10.1182/blood.V126.23.4813.4813

Published: 2015

Journal Articles

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Yuankai Shi, MD PhD, Mei Dong, MD, Jun Zhu, MD, Daobin Zhou, MD, Huiqiang Huang, MD, Ping Tu, MD, Weijing Zhang, MD, Xiaonan Hong, MD, Xielan Zhao, MD, Jianfang Sun, MD, Yuehua Liu, MD, Lugui Qiu, MD PhD, ZhiXiang Shen, MD, Jifeng Feng, MD, Xiaoyan Ke, MD PhD

Blood (2015) 126 (23): 1513.

https://doi.org/10.1182/blood.V126.23.1513.1513

Published: 2015

Journal Articles

Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, MD, Peng Wei, PhD, Shifang Yang, PhD, Xiangjun Zheng, Lugui Qiu, MD, Jian Hou, MD PhD, Xuejun Zhang, MD, Zhao Wang, Xiaoyan Ke, MD PhD, Ling Pan, MDPhD, Hongyan Pang, PhD

Blood (2014) 124 (21): 3478.

https://doi.org/10.1182/blood.V124.21.3478.3478

Published: 2014

Journal Articles

a Proposal for a New Staging System of Extranodal Natural Killer T-cell Lymphoma, Nasal-Type: a Multicenter Study of Chinese Southwest Oncology Group (CSWOG)

Blood (2014) 124 (21): 4444.

https://doi.org/10.1182/blood.V124.21.4444.4444

Published: 2014

Journal Articles

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

Xin Du, MD, Jie Jin, MD, Zhen Cai, MD, Fangping Chen, MD, Dao-bin Zhou, MD, Li Yu, MD, Xiaoyan Ke, MD PhD, Xiao Li, MD PhD, Depei Wu, MD, Fanyi Meng, MD, Dena DeMarco, Jingshan Zhang, PhD, Jay Mei, MD, Jian Hou, MD PhD

Blood (2014) 124 (21): 5737.

https://doi.org/10.1182/blood.V124.21.5737.5737

Published: 2014

Journal Articles

Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study

Renchi Yang, MD, Ming Hou, MD, Junmin Li, MD PhD, Jie Jin, MD, Meijuan Huang, MD, Ziqiang Yu, MD, Xiaojun Xu, Xiaohui Zhang, Xin Du, MD, Ting Niu, MD PhD, Xiaoyan Ke, MD PhD, Jianmin Wang, MD PhD, Jing Liu, MD, Jing Sun, MD, Yongqiang Zhao, MD& PhD, Hua Lu, MD, Haiyi Guo, MD, Belinda Hsu, Senior statistician

Blood (2014) 124 (21): 1464.

https://doi.org/10.1182/blood.V124.21.1464.1464

Published: 2014

Journal Articles

Phase Ib Study of Recombinant Circularly Permuted TRAIL (CPT) in Relapsed or Refractory multiple Myeloma Patients

Wenming Chen, MD, Lugui Qiu, MD, Jian Hou, MD, PhD, Xuejun Zhang, Xiaoyan Ke, MD, PhD, Zhao Wang, MD, PhD, Fang Zhou, Shifang Yang, PhD, Yaozhong Zhao, Yun Leng, Hao Xi, Fuxu Wang, Bing Zhu

Blood (2012) 120 (21): 1857.

https://doi.org/10.1182/blood.V120.21.1857.1857

Published: 2012

Journal Articles

Circularly Permuted TRAIL (CPT) combined with Thalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial.

Wenming Chen, MD, Jian Hou, MD, PhD, Yaozhong Zhao, Lugui Qiu, MD, Xiaoyan Ke, MD, PhD, Zhao Wang, MD, PhD, Yun Leng, Hongmei Jing, Hao Xi, Xiangjun Zheng, Fuxu Wang, Bing Zhu, Shifang Yang, PhD

Blood (2012) 120 (21): 2958.

https://doi.org/10.1182/blood.V120.21.2958.2958

Published: 2012

Journal Articles

A Multi-Center, Open-Label Phase II Study of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma - the MM-021 Trial

Jian Hou, MD, PhD, Jie Jin, MD, Zhen Cai, Fangping Chen, Li Yu, Dao-bin Zhou, MD, Xiao Li, MD, PhD, Xiaoyan Ke, MD, PhD, Depei Wu, MD, Huisheng Ai, Fanyi Meng, MD, Jianmin Wang, Jay Mei, MD, PhD, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Xin Du, PhD

Blood (2012) 120 (21): 1864.

https://doi.org/10.1182/blood.V120.21.1864.1864

Published: 2012

NARROW

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

B7-H6 Is Associated with Poor Prognosis and a Potential Therapeutic Target of T-Lymphoblastic Lymphoma

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

The Expression and Effect of B7-H3 in Mantle Cell Lymphoma

B7-H3 Silencing By RNAi Inhibits Tumor Progression and Enhances Chemosensitivity in U937 Cells

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma

a Proposal for a New Staging System of Extranodal Natural Killer T-cell Lymphoma, Nasal-Type: a Multicenter Study of Chinese Southwest Oncology Group (CSWOG)

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study

Phase Ib Study of Recombinant Circularly Permuted TRAIL (CPT) in Relapsed or Refractory multiple Myeloma Patients

Circularly Permuted TRAIL (CPT) combined with Thalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial.

A Multi-Center, Open-Label Phase II Study of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma - the MM-021 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only